Novel adjuvant recombinant herpes zoster vaccine composition as well as preparation and application thereof

Through the combination of VZV-gE protein antigen and complex adjuvant, multiple immune pathways are activated, solving the problem of reduced protection rate and side effects of existing shingles vaccines in the elderly population, achieving a more efficient immune response and lower Production cost.

CN118924892APending Publication Date: 2024-11-12JIANGSU LEVIESTER BIOTECHNOLOGY CO LTD +1

Patent Information

Application Number
CN202411351154.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing shingles vaccine has decreased in the protection rate of the elderly, and has side effects and high production costs, making it difficult to effectively prevent the recurrence of shingles and neuralgia.

Method used

Using VZV-gE protein antigen and complex adjuvant compositions, including aluminum adjuvant, squalene oil-in-water adjuvant and CpG1018 adjuvant, enhance cellular immunity and humoral immune responses and improve immune memory by activating TLR9 and other immune pathways. Capacity and protection rate.

Benefits of technology

It significantly improves antibody levels and cytokine expression, reduces the side effects of vaccine injection, and improves the prevention effect of shingles, especially in the elderly population, which effectively reduces the risk of virus reactivation and economic burden.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924892A_ABST
    Figure CN118924892A_ABST
Patent Text Reader

Abstract

The invention relates to the field of biological medicine, in particular to a novel adjuvant recombinant herpes zoster vaccine composition as well as preparation and application thereof. The novel adjuvant recombinant herpes zoster vaccine composition comprises a gE protein antigen and a composite adjuvant, the amino acid sequence of the gE protein antigen is shown as SEQIDN0.1, the composite adjuvant is at least two of an aluminum adjuvant, a squalene oil-in-water adjuvant and a CpG oligodeoxynucleotide adjuvant, and CpG oligodeoxynucleotide is CpG1018. The vaccine composition can significantly improve expression of cytokines such as INF-gamma and IL-2 of mouse CD4 + T cells, improves the immune response level, and can effectively reduce side effects caused by vaccine injection compared with single use of a conventional aluminum adjuvant; and compared with the Qinanlietasuitable researched and developed by GSK, the cell immune response level of the Qinanlietasuitable is relatively improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine, and in particular to a novel adjuvant recombinant herpes zoster vaccine composition and a preparation and application thereof. Background Art

[0002] Herpes zoster is a disease caused by the varicella-zoster virus (VZV). Children mainly suffer from chickenpox. After chickenpox is cured, the varicella-zoster virus remains dormant in the dorsal root ganglia of the spinal cord or cranial nerve ganglia for a long time. With age, immunity gradually declines, and the herpes zoster virus gradually regains its vitality. As the trend of population aging intensifies, the incidence of herpes zoster is also gradually increasing, bringing serious problems to society and personal health. As a new type of vaccine, the recombinant herpes zoster vaccine has important research significance in the field of preventing herpes zoster.

[0003] The elderly are a vulnerable group with weakened immune function and often have multiple underlying diseases. Currently, the treatment of herpes zoster is mainly antiviral and symptomatic treatment, and there is no specific drug. In addition, the treatment process of herpes zoster is long, and the medical and economic burdens it brings cannot be underestimated. Studies have shown that the average direct economic burden of herpes zoster patients is about 1,600 yuan, and the average economic burden increases significantly with age, about 2,900 yuan for those over 65 years old.

[0004] At present, the main treatment methods are antiviral drugs such as acyclovir, which can only alleviate symptoms or shorten the course of the disease, but cannot alleviate postherpetic neuralgia (PHN). With the vigorous development of biological vaccines, herpes zoster vaccines, as a new type of vaccine, play an important role in preventing herpes zoster, so scientists are committed to the research and development of VZV vaccines to reduce the number of people suffering from the disease. Herpes zoster vaccines are mainly divided into two categories: one is live attenuated vaccines, including Bio-Tech, Wantai Bio-Tech, Shanghai Bio-Tech, etc. The other is recombinant protein vaccines, including GlaxoSmithKline (GSK), Merck (MSD), Ruike Bio-Tech, etc. At present, the more common vaccines worldwide are Varivax for varicella produced by Merck in the United States, and Varilix of GSK in the United Kingdom. They are both attenuated vaccines based on the vOka virus strain. These attenuated vaccines have reduced the incidence of varicella by more than 90%, the occurrence of related complications by 57%-90%, and the hospitalization rate by 75%-88%, but this whole virus vaccine is not safe for people with immunodeficiency and will reactivate to cause herpes zoster. There are currently two FDA-approved vaccines for shingles, one is the attenuated vaccine Zostavax produced by Merck in the United States, which, like Varivax, is derived from the Oka strain, and the other is the vaccine Shingrix produced by GSK in the United Kingdom, which consists of a recombinant form of the glycoprotein gE of VZV and the AS03 adjuvant. Although the attenuated shingles vaccine has a 70% protection rate against shingles and a 67% protection rate against PHN in adults aged 50-59 years, the effectiveness of the attenuated shingles vaccine decreases significantly with age, with only a 38% protection rate in adults aged 70 years and older. In contrast, the gE subunit shingles vaccine has been shown to be very effective across age groups, reducing the incidence of shingles by 97% in people aged 50-69 years and 90% in people aged 70 years and older. In people aged 70 years and older, the gE subunit shingles vaccine has also been shown to reduce the risk of PHN by 89%.

[0005] With the continuous development and progress of biotechnology in the vaccine industry, there are currently 9 VZV surface glycoproteins identified, namely gB, gC, gE, gH, gI, gK, gL, gM and gN. Among them, gE glycoprotein is the glycoprotein with the highest expression in VZV, plays a major role in the replication and assembly of the virus, and also mediates the spread of the virus between cells. Given that VZV-gE has strong immunogenicity and can induce the body to produce an immune response against VZV, it has become one of the main candidate antigens for VZV subunit vaccines and DNA vaccines.

[0006] However, gE protein alone cannot induce strong cellular immune responses in animal models, and adjuvants are needed to enhance antigen-specific immune responses. The AS01B adjuvant system is a liposome adjuvant containing monophosphoryl lipid A and saponin QS-21, which can induce strong cellular immune responses. However, the production scale of MPLA and QS-21 is limited due to source restrictions and cannot meet the needs of commercial production. At present, there are hundreds of adjuvants that have been confirmed and used, such as inorganic salt adjuvants (such as aluminum adjuvants); oil-water emulsion adjuvants (such as Freund's adjuvant); adjuvants targeting pattern recognition receptors (such as CpG1018, MPLA); peptide adjuvants (such as muramyl dipeptide, MDP); immunostimulatory complex adjuvants (ISCOM); surfactant molecule adjuvants (such as synthetic trehalose derivatives, TDM); cytokine adjuvants (IL-1), etc. Toll-like receptors (TLRs) and C-type lectin receptors (CLRs) on the surface of antigen-presenting cells (APCs) are recognized or activated by adjuvants. On the one hand, they upregulate the expression of MHCⅠ molecules and bind to their ligands to produce antigen-specific CD8+T cells. On the other hand, they activate co-stimulatory signals CD80 / 86, promote CD4+T cells to secrete IL-4, IL-5 and IL-6, activate B cells to produce antigen-specific antibodies, and regulate cellular immunity in the body.

[0007] CpG is a class of non-methylated cytosine guanine dinucleotide sequences, which are commonly found in bacterial genomes and have the ability to activate the innate immune pattern recognition receptor-Toll-like receptor (TLR) 9. After artificial modification, a variety of CpG oligodeoxynucleotides (ODNs) resistant to nuclease degradation have been successfully synthesized, which have multiple functions: triggering innate immune responses to protect the host from pathogens; when combined with allergens, it can stimulate Th1 cell responses, thereby inhibiting the occurrence of Th2 cell-mediated allergic asthma; enhancing the secretion of cytokines, and then enhancing the specific immune response produced after vaccination; promoting the activation of natural killer (NK) cells and cytotoxic T lymphocytes (CTL), which are used in the treatment of cancer, etc.

[0008] In summary, the immunogenicity of a single adjuvant is limited; conventional single adjuvant vaccines use relatively large amounts of adjuvant; and a composite adjuvant system can significantly improve the level of immune response. Summary of the invention

[0009] In view of the above-mentioned technical defects in the prior art, the technical problem to be solved by the present invention is to further enhance the preventive effect, improve the immune memory ability, reduce complications and sequelae, selectively enhance the cell-mediated immune response, and avoid the risks of live attenuated vaccines on the basis of the prior art, thereby providing a new formula of herpes zoster recombinant protein vaccine.

[0010] The specific technical scheme of the present invention is: A novel adjuvant recombinant herpes zoster vaccine composition comprises a gE protein antigen and a composite adjuvant, wherein the amino acid sequence of the gE protein antigen is shown in SEQ ID NO.1, and the composite adjuvant is at least two of an aluminum adjuvant, a squalene oil-in-water adjuvant, and a CpG oligodeoxynucleotide adjuvant, wherein the CpG oligodeoxynucleotide is CpG1018.

[0011] The molecular weight of the SEQ ID NO.1 is 57576.17 and the isoelectric point is 5.18.

[0012] The sequence number of the SEQ ID NO.1 is as follows: SVLRYDDFHTDEDKLDTNSVYEPYYHSDHAESSWVNRGESSRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNGDDRHKIVNVDQRQYGDV FKGDLNPKPQGQRMIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTGDAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPEIEPG VLKVLRTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHVFSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNS GCTFTSPHLAQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVAYTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRY.

[0013] According to different structures, CpG ODNs are mainly divided into three categories: A, B, and C. CpG1018 used in this study belongs to type B. Type B CpG ODN can activate the TLR9 receptor. The activated TLR9 induces a strong Th1 immune response and promotes the secretion of IFN-γ and other cytokines. Human B cells and plasmacytoid dendritic cells highly express TLR9 and respond to CpG stimulation, thereby initiating an immune stimulation cascade reaction, ultimately leading to the maturation, differentiation or proliferation of NK cells, T cells, monocytes and macrophages. CpG1018 can also enhance the production of antigen-specific antibodies, especially the production of IgG2a subtype, which is very important in resisting certain bacterial infections.

[0014] Preferably, the content of the gE protein antigen is 20-80 μg / mL.

[0015] Furthermore, the present invention also discloses a pharmaceutical excipient combination for maintaining the stability of gE protein antigen, wherein the pharmaceutical excipient combination comprises: a polysorbate 80 content of 0.02-0.05%; and a phosphate buffer concentration of 10-30 mM.

[0016] Preferably, the aluminum adjuvant is aluminum hydroxide adjuvant, and the content is 300-800 μg / mL.

[0017] Preferably, the volume of the squalene oil-in-water adjuvant is 25-50%, and the droplet diameter of the squalene oil-in-water adjuvant is about 150-180 nm.

[0018] Preferably, the CpG oligodeoxynucleotide adjuvant content is 25-400 μg / mL.

[0019] Preferably, the squalene oil-in-water adjuvant comprises the following components: squalene content is 4-5wt%, Tween-80 content is 0.3-0.8wt%, Span 85 content is 0.2-1wt%, and the pH of the citric acid buffer solution is adjusted to 6.5.

[0020] The composite adjuvants squalene oil-in-water adjuvant and CpG1018 used in the present invention can complement each other in action and activate different immune pathways at the same time. Squalene oil-in-water adjuvant mainly enhances immune response by promoting sustained presentation of antigens and local inflammatory response, while CpG1018 directly promotes the activation of B cells and pDCs by activating TLR9. This combination can simultaneously enhance humoral immunity (through antibody production) and cellular immunity (through activation of T cells and NK cells), thereby achieving more comprehensive immune protection.

[0021] Preferably, the novel adjuvant recombinant herpes zoster vaccine composition has an osmotic pressure of 140-200 mOsmol / kg, an average particle size of 130-160 nm, and a pH of 7.0-7.5.

[0022] Furthermore, the cellular immunity of the novel adjuvant recombinant herpes zoster vaccine composition prepared by the present invention is a Th1 type cellular immune response.

[0023] Preferably, the gE protein antigen is stored in an antigen buffer, which contains an aqueous solution of the following components: 8-12wt% phosphate buffer, 0.01-0.05wt% Tween-80, and a solution pH of 7.2-7.8.

[0024] The present invention also discloses a method for preparing a novel adjuvant recombinant herpes zoster vaccine composition, comprising the following steps: (1) Adding phosphate buffer and Tween-80 to the antigen buffer and adjusting the pH to obtain an antigen stock solution; (2) preparing different composite adjuvants according to the mass ratio; (3) Mix the antigen stock solution, different composite adjuvants and phosphate buffer and stir evenly, protect from light, and mix by pipetting for 3-8 minutes to obtain the novel adjuvant recombinant herpes zoster vaccine composition.

[0025] The novel adjuvant recombinant herpes zoster vaccine composition is used in preparing medicines for treating or preventing diseases caused by varicella zoster virus.

[0026] Beneficial technical effects: Compared with the prior art, the present invention has the following advantages: 1. The novel adjuvant recombinant herpes zoster vaccine composition of the present invention uses VZV-gE protein, squalene oil-in-water combination adjuvant and CpG1018 adjuvant, showing significant improvement in immunogenicity and cytokine expression, and is used to increase the level of antigen-induced antibodies and the level of antigen-induced active CD4+T cells. The combination of squalene oil-in-water combination adjuvant and CpG1018 has a synergistic effect and is more effective than using these adjuvants alone. The combination achieves comprehensive activation of the immune system, including strengthening humoral immunity and cell-mediated immune responses, and can significantly increase the expression of cytokines such as INF-γ and IL-2 by CD4+T cells.

[0027] 2. The new adjuvant recombinant herpes zoster vaccine composition provided by the present invention, at the humoral immune response level, the combination of gE protein and squalene adjuvant and CpG1018 composition can effectively promote B lymphocyte response to enhance the production of specific IgG antibodies. Compared with the use of conventional aluminum adjuvants alone, it can effectively reduce the side effects caused by vaccine injection; compared with Shingrix developed by GSK, its cellular immune response level is significantly improved, effectively preventing the recurrence of herpes zoster, and plays an important role in preventing herpes zoster.

[0028] 3. The novel adjuvant recombinant herpes zoster vaccine composition provided by the present invention, at the level of cellular immune response, the gE protein combined with squalene adjuvant and the CpG1018 composition can effectively promote Th1 cell response to enhance the secretion of cytokines IFN-γ and IL-2. IL-2 can effectively activate CD4+ and CD8+ T cells and form memory phenotypes, promote the differentiation of CD4+ T cells into Th1 and Th2 cells, and IFN-γ promotes the killing of herpes zoster virus. The coordinated action of the two prevents the reactivation of the virus, controls the intracellular infection of the virus, and maintains the latent state of the virus, playing an important role in preventing the occurrence of herpes zoster.

[0029] 4. The present invention adjusts the dosage based on the excellent effect of the adjuvant, reduces production costs, and reduces vaccine side effects and sequelae.

[0030] 5. The present invention makes full use of existing detection technology and can efficiently, accurately and stably react to immune response levels, providing good support for adjuvant formulation screening. BRIEF DESCRIPTION OF THE DRAWINGS

[0031] The present invention will be further described in detail below in conjunction with the accompanying drawings and specific embodiments, and the above and / or other advantages of the present invention will become more clear.

[0032] Figure 1 This is the analysis chart of serum antibody subtype IgG titer 28 days after the second immunization of each test group; Figure 2 This is the gE-specific cell-mediated IL-2 immune response level (ELISpot) diagram; Figure 3 This is the gE-specific cell-mediated IFN-γ immune response level (ELISpot) diagram; Figure 4 The results of ELISPOT testing of CD4+T cell responses in each test group 14 days after the second immunization with the vaccine; Figure 5 The results of CD4+T cell response detected by flow cytometry 14 days after the second immunization of each test group; Figure 6 This is a graph showing the gE protein-specific cell-mediated IFN-γ, TNF-α, and IL-2 immune response levels (ICS) in group 10. DETAILED DESCRIPTION

[0033] In the present invention, unless otherwise specified, the scientific and technical terms used herein have the meanings commonly understood by those skilled in the art. In addition, the terms and laboratory procedures related to protein and nucleic acid chemistry, molecular biology, cell and tissue culture, microbiology, and immunology used herein are the terms and routine procedures widely used in the corresponding fields.

[0034] The technical scheme of the present invention will be further described in detail below in conjunction with specific embodiments. It should be understood that the following embodiments are only exemplary descriptions and explanations of the present invention and should not be construed as limiting the scope of protection of the present invention. All technologies implemented based on the above content of the present invention are included in the scope that the present invention is intended to protect.

[0035] Unless otherwise stated, the experimental methods described in the following examples are conventional methods unless otherwise stated; the raw materials and reagents are commercially available or can be prepared by known methods.

[0036] Example 1, antigen stability excipient screening, gE protein production, molecule A2 is a recombinant protein antigen for varicella-zoster virus, and DNA sequence optimization and signal peptide optimization are performed based on the amino acid sequence of CHO cells. PLK002 was selected as an empty vector, and HindIII restriction site (AAGCTT) and KOZAK sequence (GCCGCCACC) were added to the front end of the signal peptide of the optimized antigen DNA sequence, and a stop codon (TGATAA) and NotI restriction site (GCGGCCGC) were added to the back end. HindIII and NotI double-digested PLK002 and 22P20-A gene synthesis sequences, and the vector and target fragment were recovered and connected respectively. Positive transformants were screened by kanamycin resistance, and the plasmid DNA of the positive transformants was sequenced and digested for identification, and the PLK002-22P20-A expression vector was successfully constructed. The KOZAK sequence (GCCGCCACC) was added to the front end of the signal peptide of the optimized antigen DNA sequence, and the stop codon (TGATAA) was added to the back end. The DNA sequence from HindIII to NotI on the PLK002 vector was replaced by 22P20-A2 through homologous recombination. Positive transformants were screened by kanamycin resistance, and the plasmid DNA of the positive transformants was sequenced and identified by enzyme digestion. Finally, PLK002-22P20-A2 was successfully constructed.

[0037] CHOK1BN suspension cells were selected as host cells and the above successfully constructed PLK002-22P20- The expression vector of A2 was transferred into the host cells by electroporation. After transfection, the cells were screened by pressure screening, step-by-step amplification, ELISA and SEC-HPLC to screen out a high-expression monoclonal strain with an expression level of 2.96 g / L, and cultured continuously. The cell density and cell viability were monitored every day. After culturing for 10-12 days, when the cell viability was lower than 80%, the culture was stopped and the culture supernatant was harvested by centrifugal filtration. The collected supernatant was clarified and filtered, the first anion chromatography, low pH incubation + deep filtration, hydrophobic chromatography, the first ultrafiltration liquid exchange, the second deep filtration, the second anion chromatography, the second ultrafiltration liquid exchange, nanofiltration, dilution and stock solution sterilization filtration to obtain the final purified sample, i.e., gE protein.

[0038] In the process of gene construction of the above gE protein antigen, the following advantages are achieved: DNA sequence optimization: Gene optimization is mainly aimed at adjusting the problems that may exist when expressing proteins in CHO cells (Chinese hamster ovary cells). CHO cells are a host cell commonly used in biopharmaceuticals. The purpose of optimization is to improve the expression level and stability of proteins. This optimization includes codon optimization, making the DNA sequence more suitable for the translation mechanism of CHO cells and improving expression efficiency.

[0039] Signal peptide optimization: The signal peptide is a short peptide sequence that guides newly synthesized proteins into the secretory pathway. Optimizing the signal peptide can ensure that the protein is correctly introduced into the secretory pathway and secreted outside the cell. This is crucial for obtaining soluble recombinant gE protein.

[0040] PLK002 vector: PLK002 is a plasmid vector used for gene expression, containing elements such as promoter, replication origin, and resistance gene. The promoter is responsible for initiating the transcription of the target gene, and the resistance gene (such as kanamycin resistance gene) is used to screen positive clones. The PLK002 vector also contains a multiple cloning site, which can easily insert the target gene.

[0041] Restriction sites: HindIII and NotI: These two restriction sites are used to insert or replace the target gene in the vector. Double restriction digestion can linearize the vector so that it can be connected to the target gene. After restriction digestion, the vector and target gene fragments are connected to construct a recombinant plasmid.

[0042] KOZAK sequence (GCCGCCACC): This is a highly conserved ribosome binding site that exists near the start codon (AUG) in eukaryotes and helps enhance translation efficiency. Placing the KOZAK sequence at the front end of the antigen DNA sequence can improve the translation efficiency of the protein.

[0043] Construction of expression vector: Through molecular cloning technology, the optimized gE protein gene sequence was inserted into the PLK002 vector to construct the PLK002-22P20-A2 expression vector. The positive clones were sequenced and identified by enzyme digestion to verify the correctness and integrity of the insertion.

[0044] 2. Transfection of CHO cells CHO-K1 BN suspension cells: CHO cells are a mammalian cell line suitable for large-scale production of complex recombinant proteins, such as gE protein. CHO-K1 BN suspension cells can be grown in serum-free medium, which is beneficial for the later purification of proteins.

[0045] Electroporation: Electroporation is a technique that uses short, high-voltage pulses to perforate the cell membrane, allowing plasmid DNA (PLK002-22P20-A2 expression vector) to enter CHO cells. Electroporation is usually highly efficient and is a common method for introducing plasmid DNA into CHO cells.

[0046] Pressure screening and step-by-step amplification: The transfected cells are screened in a culture medium containing kanamycin to select cells carrying the resistance gene for growth. Step-by-step amplification is to obtain a monoclonal cell line that stably expresses high levels of gE protein.

[0047] 3. Screening and cultivation of high-expressing monoclonal strains ELISA and SEC-HPLC screening: ELISA (enzyme-linked immunosorbent assay): Detect the expression of gE protein in the culture supernatant. The protein expression level is quantitatively detected by binding specific antibodies to gE protein.

[0048] SEC-HPLC (size exclusion high performance liquid chromatography): detects the purity and aggregation state of the protein and screens out cell lines with high expression and stable protein.

[0049] Subculture: Select highly expressed monoclonal cell lines for subculture, and continuously monitor cell density and viability. Usually culture for 10-12 days. When cell viability is less than 80%, stop culturing and harvest supernatant.

[0050] 4. Purification of gE protein, centrifugal filtration and clarification filtration: Centrifugation: Remove cell debris by high-speed centrifugation to obtain culture supernatant.

[0051] Clarification filtration: further remove large particle impurities and prepare for subsequent purification steps. The first anion exchange chromatography: using the charge properties of the protein at a specific pH value, the gE protein is separated from impurities by ion exchange resin. The protein binds to the ion exchange resin under specific pH conditions, and then the protein is eluted by changing the pH or salt concentration. Low pH incubation + deep filtration: Low pH incubation: Treating proteins under low pH conditions helps to remove potential viruses and other contaminants. Deep filtration: removes precipitates and particulates produced after low pH treatment. Hydrophobic chromatography: based on the hydrophobic properties of the protein surface, hydrophobic resins are used for separation and purification. Hydrophobic chromatography helps to remove hydrophobic impurities and improve protein purity.

[0052] First ultrafiltration solution exchange: Ultrafiltration: Concentrate the protein solution and replace the buffer, remove small molecule impurities and adjust the protein concentration. Second anion exchange chromatography: The protein is further purified to remove remaining impurities and improve the purity of the gE protein.

[0053] Second ultrafiltration, liquid exchange and nanofiltration: Ultrafiltration: Concentrate the protein again and replace it with the final storage buffer to finally obtain highly pure gE protein.

[0054] The relative stability of the gE protein prepared above was determined under pH 7.5. Screening based on the buffer range of commonly used buffer systems showed that the SEC-HPLC and RP-HPLC purity of the 30mMPB prescription was almost unchanged compared with the 10mMPB, 20mMPB and Tris prescriptions. Samples were prepared according to the formula in Table 1 for stability testing. The protective effect of the protein under high temperature conditions (25°C), accelerated conditions (2-8°C), long-term conditions (-80°C), and repeated freezing and thawing was studied, and the changes in appearance, protein concentration, protein purity, and binding activity before and after sample treatment were evaluated. The specific stability test parameters and steps are as follows: Accelerated conditions (2-8℃), sampling points: 0d, 1W, 2W, 4W, 3M.

[0055] Long-term conditions (-80℃), sampling points: 0d, 2W, 4W, 3M.

[0056] Freeze at -80℃, thaw at room temperature, sampling points: 0d, 3 times, 5 times.

[0057] The test results show that in 30mMPB buffer, in the formulations containing and not containing trehalose, the differences in the various test items in the stability study were not obvious. During the storage process, the SEC-HPLC and RP-HPLC purity did not decrease significantly, and the binding activity did not change significantly. However, surfactants can improve the appearance and SEC-HPLC purity of the stock solution under freeze-thaw conditions, and surfactants need to be added to the stock solution formulation. (The formulation DS-F3 without surfactant under -80℃ conditions had translucent small particles in appearance after 2 weeks; the data of freeze-thaw three and five times showed that the formulation DS-F3 without surfactant appeared as a white suspension with a few translucent small particles, and the SEC-HPLC main peak decreased by ~2% accordingly.).

[0058] The test results show that the stock solution formulation is 30mMPB, pH7.5, 0.02% polysorbate 80, the protein concentration is 1~5mg / ml, and the purity and binding activity have no significant changes under the conditions of freezing and thawing 5 times, 2~8℃ and -80℃ for 3 months. The test results are shown in Table 1, Table 1-2, Table 1-2, Table 1-3 below. The main function of polysorbate in the stock solution formulation is to overcome the aggregation caused by interfacial tension during the freezing of the stock solution. Polysorbate 80 can be used as a protective agent in the freezing process.

[0059] Table 1 Prescription information of stock solution

[0060] Table 1-1 Original solution formula confirmation - 80℃ stability data

[0061] Table 1-2 Confirmation of the stability data of the stock solution at 2~8℃

[0062] Table 1-3 Stability data of freeze-thaw conditions for stock solution formulation confirmation

[0063] Example 2 Prescription screening and property testing of new adjuvant recombinant herpes zoster vaccine composition.

[0064] For animal experiments, 6-8 week old C57BL / 6 mice were selected, 6 mice in each group, and randomly divided into groups. Each mouse was immunized twice with an interval of 28 days, and different doses of vaccine were injected intramuscularly (Table 2). The single administration volume was 50 μL / mouse, and the corresponding amount of administration preparation was accurately drawn for intramuscular injection. The day of the first immunization was defined as day 0 of the experiment. Blood was collected 28 days after the second administration for binding antibody detection, and the mouse spleen was separated to prepare fresh mouse spleen lymphocytes, which were cultured overnight in a cell culture incubator at 37°C and 5% CO2. The immune response effect was detected by enzyme-linked immunospot assay (ELISpot assay) and flow cytometry assay (ICS assay).

[0065] Table 2 Amount of each component in the vaccine composition

[0066] Binding antibody titer detection (ELISA assay) ELISA can detect the binding antibody titer at the humoral immune level. The specific operation is as follows: first dilute the antigen protein with alkaline coating buffer and add it to the ELISA plate at 4°C overnight. The next day, discard the coating solution, wash the ELISA plate with PBST, pat dry, add the blocking solution, and incubate at 37°C for 1h. Discard the blocking solution, wash the ELISA plate with PBST, pat dry, and mark the plate with group numbers. Add the diluted serum to the corresponding well plate and incubate at 37°C for 1h. Discard the serum diluent, wash the ELISA plate with PBST, pat dry, add the diluted secondary antibody, and incubate at 37°C for 1h. Discard the secondary antibody, wash the ELISA plate with PBST, pat dry, add the colorimetric solution, and stand at room temperature in the dark for 5-10min. Add the stop solution to stop the reaction when the color of the well plate shows a clear gradient, and detect the OD450 reading value by the ELISA reader.

[0067] VZV-gE antigen-specific IgG titers were measured according to the above method. Figure 1 As shown, compared with the positive control group and other experimental groups, the expression level of gE antigen-specific IgG increased after the second immunization. The results show that at the humoral immune response level, the combination of gE protein and squalene adjuvant and CpG1018 composition can effectively promote B lymphocyte response to enhance the production of specific IgG antibodies, effectively prevent the recurrence of herpes zoster, and play an important role in preventing herpes zoster.

[0068] Cellular immunoassay (ELISpot assay), ELISpot detection can measure VZV antigen-specific cell-mediated immune responses. The specific operation is as follows: first incubate, make 2 parallel controls for each sample, and culture in a cell culture incubator at 37°C, 5% CO2 for about 36 hours. Then dilute the specific detection antibody (secondary antibody) and add it to the ELISpot plate and place it at room temperature for 2 hours. Discard the liquid in the plate, wash it with PBS 5 times, add the diluted enzyme conjugate to the ELISpot plate, and place it at room temperature for 1 hour. Filter the substrate with a 0.45μm filter membrane and add it to each well. After reacting for 5 minutes, obvious spots appear. Rinse with a large amount of distilled water to terminate the reaction and count the spots.

[0069] VZV-gE antigen-specific cell-mediated immune responses were measured according to the above method, and the experimental results are shown in Figure 2 and Figure 3 , where Figure a is a negative control, and Figure b is the cellular immune assay results of gE (5μg) + squalene water-in-oil adjuvant (12.5μl) + CpG1018 (10μg) in Group 8. From the results, it can be seen that the level of gE-specific cell-mediated IL-2 immune response in the example after the second immunization is very obvious.

[0070] like Figure 4 As shown, compared with the positive control group and other experimental groups, the gE antigen-specific cell-mediated immune response in the embodiment after the second immunization was significantly improved. The results show that at the level of cellular immune response, the gE protein combined with squalene adjuvant and the CpG1018 composition can effectively promote Th1 cell response to enhance the secretion of cytokines IFN-γ and IL-2. IL-2 can effectively activate CD4+ and CD8+ T cells and form memory phenotypes, promote the differentiation of CD4+ T cells into Th1 and Th2 cells, and IFN-γ promotes the killing of herpes zoster virus. The coordinated action of the two prevents the reactivation of the virus, controls the intracellular infection of the virus, and maintains the latent state of the virus, playing an important role in preventing the occurrence of herpes zoster.

[0071] Cytokine secretion assay (ICS assay) and flow cytometry assay (ICS assay) can determine lymphocyte subsets and their cytokine distribution. The specific operation is as follows: Fresh mouse spleen lymphocytes are cultured overnight in a 37°C, 5% CO2 cell culture incubator. Add the stimulants to the wells with existing cells, mix well, and culture in a 37°C, 5% CO2 cell culture incubator. After stimulation, the blocking agent is diluted with culture medium and added to the cells for continued culture. Add PBS, centrifuge at 600×g for 5 minutes at room temperature, discard the supernatant, perform Live / Dead staining, place at room temperature away from light for 20 minutes, then perform surface staining, and place at room temperature away from light for 20 minutes. Dilute the IC fixation buffer with staining buffer, add the IC fixation buffer and resuspend the cells, place at room temperature away from light for 30 minutes, centrifuge at 600×g for 5 minutes at room temperature, and discard the supernatant. Prepare each intracellular fluorescent labeled antibody (IFN-γ antibody, IL-2 antibody, TNF-α antibody) and place at room temperature away from light for 60 minutes for intracellular staining. Finally, the cells were washed and the distribution of T cells and corresponding cytokine secretion caused by antigen stimulation was detected.

[0072] The VZV-gE antigen-specific cell-mediated lymphocyte subsets and their cytokine secretion were measured according to the above method. The experimental results are shown in Figure 5 As shown, compared with the negative control, when the adjuvant aluminum hydroxide and CpG1018 combination or the squalene oil-in-water combination adjuvant and CPG1018 combination is used, the prepared recombinant herpes zoster vaccine composition can produce a certain level of induction of IFN-γ, TNF-α, and IL-2, and the recombinant herpes zoster vaccine composition prepared by the dual adjuvant system of squalene oil-in-water combination adjuvant and CPG1018 can induce high levels of IFN-γ, TNF-α, and IL-2; in the composite adjuvant group, squalene oil-in-water combination adjuvant (25μl) + CpG1018 (10μg) performed best, and was superior to the Shingrix group in the ability to induce IFN-γ and IL-2 secretion.

[0073] After the second immunization, the amount of cytokines secreted by CD4+T lymphocytes mediated by gE antigen-specific cells in the example was increased. Figure 6 As shown, at the level of cellular immune response, the combination of gE, squalene oil-in-water adjuvant and CpG1018 can effectively promote Th1 cell response to enhance the secretion of cytokines IL-2, IFN-γ and TNF-α, activate CD4+ and CD8+ T cells and form memory phenotypes, promote the differentiation of CD4+ T cells into Th1 and Th2 cells, prevent viral reactivation, and play an important role in preventing herpes zoster.

[0074] VZV-specific cellular immunity is the main determinant of the risk and severity of herpes zoster. Antigen-specific T cells can inhibit VZV reactivation in infected cells, so cellular immunity can control the incidence of herpes zoster. Therefore, when analyzing the test data, we focus on the expression of cytokines such as INF-γ and IL-2 obtained by ELISpot and flow cytometry (ICS) tests, which reflect the level of cell-mediated immune response.

[0075] The embodiments are all recombinant herpes zoster vaccine compositions in different combinations proposed by the present invention. In the embodiments, VZV-gE protein, squalene oil-in-water combination adjuvant and CpG1018 adjuvant were used, showing a significant improvement in immunogenicity and cytokine expression. This shows that the combination of squalene oil-in-water combination adjuvant and CpG1018 has a synergistic effect and is more effective than using these adjuvants alone. The combination achieves a comprehensive activation of the immune system, including strengthening humoral immunity and cell-mediated immune responses, especially by promoting the production of IFN-γ, TNF-α and IL-2, which are essential for resisting infection and disease.

[0076] VZV-gE was stored in a freeze-dried form. Before adding the squalene oil-in-water combination adjuvant and the CpG adjuvant system, the long-term, accelerated and high-temperature stability of Group 10 with better immunogenicity was examined, and the stability of the adjuvant system was also examined.

[0077] High temperature condition (40°C), sampling points: 0d, 1W, 2W, 4W; Accelerated conditions (25°C), sampling points: 0d, 1M, 2M, 3M; Long-term conditions (2~8℃), sampling points: 0d, 1M, 2M, 3M.

[0078] After being placed at 40℃ for 4 weeks, 25℃ for 3 months and 2-8℃ for 3 months, there were no significant changes in the particle size, squalene content, polysorbate 80 content and Span 85 content of the squalene combination adjuvant system.

[0079] After the gE protein lyophilized powder was placed at 25°C and 2-8°C for 3 months, there was no significant change in gE content, SEC-HPLC, and RP-HPLC. The results are shown in Tables 3 and 4. The stability of the VZV-gE lyophilized powder and the adjuvant system was good and met the requirements for vaccine preparation.

[0080] Table 3gE protein freeze-dried powder stability results

[0081] Table 4 Compound adjuvant stability test conditions

[0082] The present invention provides a recombinant herpes zoster vaccine composition and its preparation method and application ideas and methods. There are many methods and approaches to specifically implement the technical solution. The above is only a preferred embodiment of the present invention. It should be pointed out that for technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. A novel adjuvant recombinant herpes zoster vaccine composition, characterized in that: It comprises a gE protein antigen and a composite adjuvant, wherein the amino acid sequence of the gE protein antigen is shown in SEQ ID NO.1, and the composite adjuvant is at least two of an aluminum adjuvant, a squalene oil-in-water adjuvant, and a CpG oligodeoxynucleotide adjuvant, wherein the CpG oligodeoxynucleotide is CpG1018.

2. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 1, characterized in that: The content of the gE protein antigen is 20-80 μg / mL.

3. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 1, characterized in that: The aluminum adjuvant is aluminum hydroxide adjuvant, and the content is 300-800 μg / mL.

4. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 1, characterized in that: The volume of the squalene oil-in-water adjuvant is 25-50%, and the droplet diameter of the squalene oil-in-water adjuvant is about 150-180 nm.

5. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 1, characterized in that: The content of the CpG oligodeoxynucleotide adjuvant is 25-400 μg / mL.

6. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 4, characterized in that: The squalene oil-in-water adjuvant comprises the following components: squalene content is 4-5wt%, Tween-80 content is 0.3-0.8wt%, Span 85 content is 0.2-1wt%, and citric acid buffer solution is used to adjust pH.

7. The novel adjuvant recombinant herpes zoster vaccine composition according to any one of claims 1 to 6, characterized in that: The novel adjuvant recombinant herpes zoster vaccine composition has an osmotic pressure of 140-200 mOsmol / kg, an average particle size of 130-160 nm, and a pH of 7.0-7.

5.

8. The novel adjuvant recombinant herpes zoster vaccine composition according to claim 1, characterized in that: The gE protein antigen is stored in an antigen buffer, which contains an aqueous solution of the following components: 8-12wt% phosphate buffer, 0.01-0.05wt% Tween-80, and a solution pH of 7.2-7.

8.

9. The method for preparing the novel adjuvant recombinant herpes zoster vaccine composition according to any one of claims 1 to 8, characterized in that: The following steps are involved: (1) Adding phosphate buffer and Tween-80 to the antigen buffer and adjusting the pH to obtain an antigen stock solution; (2) preparing different composite adjuvants according to the mass ratio; (3) Mix the antigen stock solution, different composite adjuvants and phosphate buffer and stir evenly, protect from light, and mix by pipetting to obtain the novel adjuvant recombinant herpes zoster vaccine composition.

10. Use of the novel adjuvant recombinant herpes zoster vaccine composition according to any one of claims 1 to 8 in the preparation of a medicament for treating or preventing a disease caused by varicella zoster virus.

Citation Information

Patent Citations

  • Composite vaccine adjuvant and application thereof

    CN107184973A

  • Process for determining a humoral response in an immunodepressed patient

    CN108431604A

  • Varicella-zoster virus gE protein mutant and expression method thereof

    CN112142829A

  • Truncated varicella-zoster virus gE protein and application thereof

    CN116655748A

  • Vaccine adjuvant, and preparation method therefor and use thereof

    WO2023124116A1

Cited By

  • A CpG oligonucleotide

    CN119752901A